文献速递头颈与中枢神经肿瘤

洛铂联合氟尿嘧啶诱导化疗后同步放化疗对比顺铂方案治疗III-IVB期鼻咽癌的非劣效性III期随机对照试验

Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-04-12

该开放标签、非劣效性、随机对照III期试验在中国5家医院纳入502例III-IVB期鼻咽癌患者,比较洛铂为基础与顺铂为基础的诱导化疗后同步放化疗的疗效。洛铂组白细胞减少和中性粒细胞减少的3-4级不良事件发生率较低,无治疗相关死亡。

要点

  • 洛铂组3-4级白细胞减少(16% vs 23%)和中性粒细胞减少(10% vs 24%)更少。
  • 两组3-4级口腔黏膜炎发生率相似(41% vs 40%),无治疗相关死亡。

核心结论

  • 洛铂为基础的诱导化疗后同步放化疗在局部晚期鼻咽癌中显示出非劣效的5年无进展生存,且毒性更低。

研究设计与样本

  • 开放标签、非劣效性、随机对照III期试验,在中国5家医院进行,纳入502例18-60岁初治非角化性III-IVB期鼻咽癌患者,按1:1随机分配至洛铂组(252例)或顺铂组(250例)。

主要发现

  • 意向治疗人群中,洛铂组63例(25%) vs 顺铂组63例(25%)发生PFS事件;符合方案人群中,洛铂组62例(25%) vs 顺铂组58例(25%)发生PFS事件。
  • 最常见的3-4级不良事件为口腔黏膜炎(洛铂组102/252例[41%] vs 顺铂组99/249例[40%])、白细胞减少(39/252例[16%] vs 56/249例[23%])和中性粒细胞减少(25/252例[10%] vs 59/249例[24%])。
  • 未报告治疗相关死亡。

关键数值与推荐

  • 非劣效界值:5年PFS差异的95%CI上限不超过10%。
  • 洛铂组方案:诱导化疗洛铂30 mg/m2第1、22天,氟尿嘧啶800 mg/m2第1-5天和第22-26天,共2周期;同步放化疗洛铂30 mg/m2每3周1次,共2周期,联合调强放疗。
  • 顺铂组方案:诱导化疗顺铂100 mg/m2第1、22天,氟尿嘧啶800 mg/m2第1-5天和第22-26天,共2周期;同步放化疗顺铂100 mg/m2每3周1次,共2周期,联合调强放疗。
  • 放疗总剂量:原发肿瘤和肿大咽后淋巴结68-70 Gy,临床受累颈部淋巴结62-68 Gy,高危靶区60 Gy,低危靶区54 Gy,分30-32次,每周5天。

临床怎么用

  • 对于局部晚期鼻咽癌,洛铂为基础的诱导化疗后同步放化疗可作为顺铂方案的替代选择,尤其适用于顺铂不耐受或高毒性风险患者。

局限性

  • 开放标签设计,临床医生和患者均知晓治疗分配。
  • 研究仅在中国5家医院进行,结果外推需谨慎。
  • 未报告总生存数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cisplatin-based induction chemotherapy plus concurrent chemoradiotherapy in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma has been recommended in the National Comprehensive Cancer Network Guidelines. However, cisplatin is associated with poor patient compliance and has notable side-effects. Lobaplatin, a third-generation platinum drug, has shown promising antitumour activity against several malignancies with less toxicity. In this study, we aimed to evaluate the efficacy of lobaplatin-based induction chemotherapy plus concurrent chemoradiotherapy over a cisplatin-based regimen in patients with locoregional, advanced nasopharyngeal carcinoma. METHODS: In this open-label, non-inferiority, randomised, controlled, phase 3 trial done at five hospitals in China, patients aged 18-60 years with previously untreated, non-keratinising stage III-IVB nasopharyngeal carcinoma; Karnofsky performance-status score of at least 70; and adequate haematological, renal, and hepatic function were randomly assigned (1:1) to receive intravenously either lobaplatin-based (lobaplatin 30 mg/m2 on days 1 and 22, and fluorouracil 800 mg/m2 on days 1-5 and 22-26 for two cycles) or cisplatin-based (cisplatin 100 mg/m2 on days 1 and 22, and fluorouracil 800 mg/m2 on days 1-5 and 22-26 for two cycles) induction chemotherapy, followed by concurrent lobaplatin-based (two cycles of intravenous lobaplatin 30 mg/m2 every 3 weeks plus intensity-modulated radiotherapy) or cisplatin-based (two cycles of intravenous cisplatin 100 mg/m2 every 3 weeks plus intensity-modulated radiotherapy) chemoradiotherapy. Total radiation doses of 68-70 Gy (for the sum of the volumes of the primary tumour and enlarged retropharyngeal nodes), 62-68 Gy (for the volume of clinically involved gross cervical lymph nodes), 60 Gy (for the high-risk target volume), and 54 Gy (for the low-risk target volume), were administered in 30-32 fractions, 5 days per week. Randomisation was done centrally at the clinical trial centre of Sun Yat-sen University Cancer Centre by means of computer-generated random number allocation with a block design (block size of four) stratified according to disease stage and treatment centre. Treatment assignment was known to both clinicians and patients. The primary endpoint was 5-year progression-free survival, analysed in both the intention-to-treat and per-protocol populations. If the upper limit of the 95% CI for the difference in 5-year progression-free survival between the lobaplatin-based and cisplatin-based groups did not exceed 10%, non-inferiority was met. Adverse events were analysed in all patients who received at least one cycle of induction chemotherapy. This trial is registered with the Chinese Clinical Trial Registry, ChiCTR-TRC-13003285 and is closed. FINDINGS: From June 7, 2013, to June 16, 2015, 515 patients were assessed for eligibility and 502 patients were enrolled: 252 were randomly assigned to the lobaplatin-based group and 250 to the cisplatin-based group. After a median follow-up of 75·3 months (IQR 69·9-81·1) in the intention-to-treat population, 5-year progression-free survival was 75·0% (95% CI 69·7-80·3) in the lobaplatin-based group and 75·5% (70·0 to 81·0) in the cisplatin-based group (hazard ratio [HR] 0·98, 95% CI 0·69-1·39; log-rank p=0·92), with a difference of 0·5% (95% CI -7·1 to 8·1; pnon-inferiority=0·0070). In the per-protocol population, the 5-year progression-free survival was 74·8% (95% CI 69·3 to 80·3) in the lobaplatin-based group and 76·4% (70·9 to 81·9) in the cisplatin-based group (HR 1·04, 95% CI 0·73 to 1·49; log-rank p=0·83), with a difference of 1·6% (-6·1 to 9·3; pnon-inferiority=0·016). 63 (25%) of 252 patients in the lobaplatin-based group and 63 (25%) of 250 patients in the cisplatin-based group had a progression-free survival event in the intention-to-treat population; 62 (25%) of 246 patients in the lobaplatin-based group and 58 (25%) of 237 patients in the cisplatin-based group had a progression-free survival event in the per-protocol population. The most common grade 3-4 adverse events were mucositis (102 [41%] of 252 in the lobaplatin-based group vs 99 [40%] of 249 in the cisplatin-based group), leucopenia (39 [16%] vs 56 [23%]), and neutropenia (25 [10%] vs 59 [24%]). No treatment-related deaths were reported. INTERPRETATION: Lobaplatin-based induction chemotherapy plus concurrent chemoradiotherapy resulted in non-inferior survival and fewer toxic effects than cisplatin-based therapy. The results of our trial indicate that lobaplatin-based induction chemotherapy plus concurrent chemoradiotherapy might be a promising alternative regimen to cisplatin-based treatment in patients with locoregional, advanced nasopharyngeal carcinoma. FUNDING: National Science and Technology Pillar Program, International Cooperation Project of Science and Technology Program of Guangdong Province, Planned Science and Technology Project of Guangdong Province, and Cultivation Foundation for the Junior Teachers at Sun Yat-sen University. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lv X, Cao X, Xia WX, et al. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021. PMID: 33857411. doi:10.1016/S1470-2045(21)00075-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。